Creatine Supplementation with GFR 57 mL/min/1.73 m²
Creatine supplementation should be avoided in patients with a GFR of 57 mL/min/1.73 m² (Stage 3A CKD), as current guidelines recommend against its use in individuals with pre-existing renal disease or reduced glomerular filtration rate.
Understanding Your Kidney Function Status
Your GFR of 57 mL/min/1.73 m² places you in Stage 3A chronic kidney disease, defined as a mild-to-moderate decrease in kidney filtration (eGFR 45-59 mL/min/1.73 m²) 1. This represents approximately a 50% loss of normal kidney function compared to young healthy adults 1.
Critical Diagnostic Steps Before Any Supplement Decision
Measure urine albumin-to-creatinine ratio (UACR) immediately – this is the single most important test to determine your true kidney disease risk and guide all treatment decisions 2.
Confirm your CKD diagnosis with cystatin C measurement – approximately 23% of individuals with eGFR 45-59 mL/min/1.73 m² are misclassified when only creatinine-based equations are used 1. If cystatin C-based eGFR is also <60 mL/min/1.73 m², CKD is confirmed; if >60 mL/min/1.73 m², you may not actually have CKD 1.
Why Creatine Is Problematic in Your Situation
Guideline-Based Contraindication
Expert consensus explicitly advises against creatine supplementation in individuals with pre-existing renal disease, reduced glomerular filtration rate, diabetes, or hypertension 3. This recommendation stems from safety concerns rather than proven harm, but the precautionary principle applies when kidney function is already compromised.
The Diagnostic Confusion Problem
Creatine supplementation artificially elevates serum creatinine without actually impairing kidney function 4, 5. In a controlled study of a young man with a single kidney and mildly decreased GFR, creatine supplementation increased serum creatinine from 1.03 to 1.27 mg/dL, yet measured GFR remained unchanged (81.6 vs 82.0 mL/min/1.73 m²) 4.
This creates a dangerous clinical scenario: Your doctors rely on serum creatinine to monitor your kidney disease progression 6. If you take creatine, rising creatinine levels will falsely suggest worsening kidney function, potentially triggering unnecessary interventions, medication changes, or premature dialysis planning 7.
The effect is dose-dependent and persistent: A 2025 meta-analysis showed creatine causes a statistically significant increase in serum creatinine (MD: 0.07 µmol/L), with the effect becoming significant again in studies with follow-up >12 weeks 5.
Masking True Kidney Function
Estimated GFR equations already overestimate true kidney function in many clinical situations 8, 9. At a measured GFR of 60 mL/min/1.73 m², eGFR values can range from 61-68 mL/min/1.73 m² 8.
Adding creatine supplementation compounds this inaccuracy by further elevating serum creatinine through non-renal mechanisms (increased muscle creatine turnover), making it impossible to accurately track your kidney disease progression 6, 7.
What the Research Actually Shows
Safety Data Is Limited to Healthy Kidneys
Studies showing creatine safety were conducted in healthy individuals or those with normal kidney function 4, 3, 10. The 2025 meta-analysis included only 177 participants in creatine groups, with no long-term data in CKD populations 5.
One study in peripheral artery disease patients (mean baseline creatinine 1.00-1.30 mg/dL) showed no change in creatinine clearance after 8 weeks, but these patients had better baseline kidney function than Stage 3A CKD 10.
No high-quality studies have evaluated creatine safety specifically in Stage 3A CKD patients 3, 5.
The Precautionary Principle Applies
Even though creatine may not directly damage kidneys, the diagnostic interference alone justifies avoidance 7. You cannot safely monitor kidney disease progression while taking a supplement that artificially elevates the primary biomarker used for monitoring.
The risk-benefit ratio is unfavorable: Any potential benefits of creatine (athletic performance, muscle mass) are outweighed by the inability to accurately assess kidney function in someone with established CKD 3, 7.
What You Should Do Instead
Optimize Evidence-Based CKD Management
Target blood pressure <120/80 mmHg if tolerated, to slow CKD progression 2.
If you have albuminuria (UACR ≥30 mg/g), start an ACE-inhibitor or ARB at the highest tolerated dose 2.
Consider SGLT2 inhibitor therapy (empagliflozin, dapagliflozin, canagliflozin) if you have diabetes or significant albuminuria, as these medications reduce CKD progression and cardiovascular events even at eGFR >20 mL/min/1.73 m² 11, 2.
Initiate statin therapy for cardiovascular risk reduction 2.
Monitoring Strategy
Repeat eGFR and UACR every 3-6 months given your Stage 3A status 2.
Avoid nephrotoxic medications including NSAIDs, certain antibiotics, and contrast dye when possible 12.
Common Pitfalls to Avoid
Do not assume your kidney function is "only mildly decreased" – Stage 3A CKD carries moderate risk for progression, and this risk escalates dramatically if albuminuria is present 1.
Do not rely on serum creatinine alone – it substantially underestimates kidney dysfunction, especially in older adults, women, and individuals with low muscle mass 1.
Do not take creatine "just to try it" – even short-term use will compromise your ability to accurately monitor kidney function for months afterward 5.